Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers
Manji, H.K.; Moore, G.J.; Chen, G.
British Journal of Psychiatry. Suppl 41: S107-S119
2001
ISSN/ISBN: 0960-5371 PMID: 11450170 Document Number: 538930
New research is dramatically altering our understanding of the molecular mechanisms underlying neuronal communication. To elucidate the molecular mechanisms underlying the therapeutic effects of mood stabilizers. Results from integrated clinical and laboratory studies are reviewed. Chronic administration of lithium and valproate produced a striking reduction in protein kinase C (PKC) isozymes in rat frontal cortex and hippocampus. In a small study, tamoxifen (also a PKC inhibitor) had marked antimanic efficacy. Both lithium and valproate regulate the DNA binding activity of the activator protein I family of transcription factors. Using mRNA differential display, it was also shown that chronic administration of lithium and valproate modulates expression of several genes. An exciting finding is that of a robust elevation in the levels of the cytoprotective protein, bcl-2. The results suggest that regulation of signalling pathways may play a major part in the long-term actions of mood stabilizers. Additionally, mood stabilizers may exert underappreciated neuroprotective effects.